Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

In cancer patients, dormant micrometastases are often asymptomatic and clinically undetectable, for months or years, until relapse. We have studied dormant lung metastases under angiogenesis suppression in mice. The metastases exhibited rapid growth when the inhibition of angiogenesis was removed. Tumour cell proliferation, as measured by bromodeoxyuridine incorporation and immunohistochemical staining proliferating cell nuclear antigen, was not significantly different in dormant and growing metastases. However, tumour cells of dormant metastases exhibited a more than threefold higher incidence of apoptosis. These data show that metastases remain dormant when tumour cell proliferation is balanced by an equivalent rate of cell death and suggest that angiogenesis inhibitors control metastatic growth by indirectly increasing apoptosis in tumour cells.

[1]  K. Weinhold,et al.  The tumor dormant state. , 1981, Advances in cancer research.

[2]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[3]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[4]  R. Sasada,et al.  Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. , 1991, Cancer research.

[5]  M. Woodruff The Walter Hubert Lecture, 1982. Interaction of cancer and host. , 1982, British Journal of Cancer.

[6]  M. Raff,et al.  Social controls on cell survival and cell death , 1992, Nature.

[7]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[8]  H. Seigler,et al.  Relationship between disease-free interval and survival in patients with recurrent melanoma. , 1992, Archives of surgery.

[9]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[10]  G. Nicolson,et al.  Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. , 1992, British Journal of Cancer.

[11]  R. Noble,et al.  A classification of transplantable tumors in Nb rats controlled by estrogen from dormancy to autonomy. , 1975, Cancer research.

[12]  David P. LeBrun,et al.  Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice , 1993, Cell.

[13]  R. Nicosia,et al.  Angiogenesis-dependent tumor spread in reinforced fibrin clot culture. , 1983, Cancer research.

[14]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[15]  A. Meltzer,et al.  Dormancy and breast cancer , 1990, Journal of surgical oncology.

[16]  S. Koscielny,et al.  Re: Local recurrences following mastectomy: support for the concept of tumor dormancy. , 1994, Journal of the National Cancer Institute.

[17]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[18]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[19]  G. Evan,et al.  Oncogenes and cell death. , 1994, Current opinion in genetics & development.

[20]  H. Gratzner,et al.  Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. , 1982, Science.

[21]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[22]  W. Richardson,et al.  Cell death and control of cell survival in the oligodendrocyte lineage , 1992, Cell.

[23]  J. Folkman,et al.  Analysis of experimental antiangiogenic therapy. , 1993, Journal of pediatric surgery.

[24]  E. White,et al.  Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins , 1991, Journal of virology.

[25]  D. Ingber,et al.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.

[26]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[27]  J. Folkman Angiogenesis and breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Steeg,et al.  Angiogenesis and colonization in the tumor metastatic process: basic and applied advances , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  W. Bursch,et al.  Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. , 1990, Carcinogenesis.

[30]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[31]  V. Castronovo,et al.  AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. , 1994, Cancer research.

[32]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[33]  L. Ellis,et al.  The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.

[34]  J. Folkman What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.